Phase 1/2Completed
Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours
- Sponsor
- Noxopharm Limited (Industry)
- Enrollment
- 19 enrolled
- Conditions
- Cancer
- Interventions
- NOX66; Carboplatin
- Ages
- adults, older adults
- Registry
- NCT02941523
Full record on ClinicalTrials.gov
From the registry
The study evaluates the safety and activity of NOX66 in patients with refractory solid tumors that are non responsive to standard therapies. This is a two part with a potential third part, open-label, multicenter, dose escalation study of NOX66 as monotherapy and in combination with carboplatin.
Primary outcomes
- Number of Participants Who Experience Dose Limiting Toxicity (DLT) During NOX66 Monotherapy and During NOX66 Combination With Carboplatin
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Treatment Emergent Adverse Events (SAEs) Related to NOX66.
History
Results first posted
Last registry update
Study completion
Primary completion
Started
Registered